Stevens-Johnson syndrome in a boy with macrolide-resistant Mycoplasma pneumoniae pneumonia

Pediatrics

Volumn 127, Issue 6, 2011, Pages

  Atkinson, T Prescott ^a   Boppana, Suresh ^a   Theos, Amy ^b   Clements, L Scott ^c   Xiao, Li ^d   Waites, Ken ^d  

^a University of Alabama at Birmingham and Children's Hospital   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Drug resistance; Mycoplasma pneumoniae; Pneumonia; Stevens Johnson syndrome

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MORPHINE; RNA 16S; TOBRAMYCIN;

ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BULLOUS SKIN DISEASE; CASE REPORT; CHILD; COUGHING; DESQUAMATION; DISEASE ASSOCIATION; ERYTHEMA; FEVER; GENE; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIAE; MALAISE; MALE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; OXYGEN THERAPY; PAIN; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPMP GENE; SCHOOL CHILD; SKIN BIOPSY; SKIN DISEASE; SORE THROAT; STEVENS JOHNSON SYNDROME; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VESICULAR RASH;

EID: 79957903587     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-2624     Document Type: Article

References (45)

1. Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67(4):355-358
2. Xin D, Mi Z, Han X, et al. Molecular mechanismsof macrolide resistance in clinical isolates ofMycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53(5):2158-2159
3. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008;52(10):3542-3549
4. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635-648
5. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956-973
6. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697-728 (Pubitemid 39372513)
7. Dumke R, Schurwanz N, Lenz M, Schuppler M, Luck C, Jacobs E. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. J Clin Microbiol. 2007;45(8):2726-2730 (Pubitemid 47295516)
8. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009;28(8):693-696
9. Sabato AR, Martin AJ, Marmion BP, Kok TW, Cooper DM. Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function. Arch Dis Child. 1984;59(11):1034-1037 (Pubitemid 15209597)
10. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85(2):131-138
11. Foy HM, Nolan CM, Allan ID. Epidemiologic aspects of M pneumoniae disease complications: a review. Yale J Biol Med. 1983;56(5-6):469-473 (Pubitemid 14052700)
12. Ludlam GB, Bridges JB. Association of Stevens-Johnson syndrome with antibody for Mycoplasma pneumoniae. Lancet. 1964;1(7340):958-959
13. Katz HI, Wooten JW, Davis RG, Griffin JP. Stevens-Johnson syndrome: report of a case associated with culturally proven Mycoplasma pneumoniae infection. JAMA. 1967;199(7):504-506
14. Griffiths PD. Mucocutaneous reactions during Mycoplasma pneumoniae infection. Lancet. 1978;1(8071):988 (Pubitemid 8337737)
15. Sontheimer RD, Garibaldi RA, Krueger GG. Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infections. Arch Dermatol. 1978;114(2):241-244
16. Swift PG, Stevens DW. Mucocutaneous reactions during Mycoplasma pneumoniae infection. Lancet. 1978;1(8073):1104-1105 (Pubitemid 8356393)
17. McCormack JG. Mycoplasma pneumoniae and the erythema multiforme-Stevens Johnson syndrome. J Infect. 1981;3(1):32-36 (Pubitemid 11101098)
18. Levy M, Shear NH. Mycoplasma pneumoniae infections and Stevens-Johnson syndrome: report of eight cases and review of the literature. Clin Pediatr (Phila). 1991;30(1):42-49
19. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5 pt 1):757-760 (Pubitemid 26389476)
20. Sendi P, Graber P, Lepere F, Schiller P, Zimmerli W. Mycoplasma pneumoniae infection complicated by severe mucocutaneous lesions. Lancet Infect Dis. 2008;8(4):268 (Pubitemid 351391991)
21. Meseguer MA, de Rafael L, Vidal ML. Stevens-Johnson syndrome with isolation of Mycoplasma pneumoniae from skin lesions. Eur J Clin Microbiol. 1986;5(2):167-168 (Pubitemid 16112909)
22. Stutman HR. Stevens-Johnson syndrome and Mycoplasma pneumoniae: evidence for cutaneous infection. J Pediatr. 1987;111(6 pt 1):845-847 (Pubitemid 18019156)
23. Welch KJ, Burke WA, Irons TG. Recurrent erythema multiforme due to Mycoplasma pneumoniae. J Am Acad Dermatol. 1987;17(5 pt 1):839-840
24. Taylor-Robinson D, Webster AD, Furr PM, Asherson GL. Prolonged persistence of Mycoplasma pneumoniae in a patient with hypogammaglobulinaemia. J Infect. 1980;2(2):171-175 (Pubitemid 10086076)
25. Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med. 1986;80(4):590-594 (Pubitemid 16035574)
26. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160-2162
27. Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52(1):348-350
28. Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation [published correction appears in Antimicrob Agents Chemother. 2005;49(7):3100]. Antimicrob Agents Chemother. 2005;49(6):2302-2306 (Pubitemid 40734458)
29. Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64(1):52-58
30. Dumke R, von Baum H, Luck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010;16(6):613-616
31. Biberfeld G. Distribution of antibodies within 19 S and 7 S immunoglobulins following infection with Mycoplasma pneumoniae. J Immunol. 1968;100(2):338-347
32. Atkinson TP, Duffy LB, Pendley D, Dai Y, Cassell GH. Deficient immune response to Mycoplasma pneumoniae in childhood asthma. Allergy Asthma Proc. 2009;30(2):158-165
33. Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced cutaneous disease. Int J Dermatol. 2009;48(7):673-680; quiz 680-671
34. Nilsson AC, Bjorkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol. 2008;8:93
35. Slotkin RI, Clyde WA Jr, Denny FW. The effect of antibiotics on Mycoplasma pneumoniae in vitro and in vivo. Am J Epidemiol. 1967;86(1):225-237
36. Biberfeld G, Sterner G. A study of Mycoplasma pneumoniae infections in families. Scand J Infect Dis. 1969;1(1):39-46
37. Foy HM, Grayston JT, Kenny GE, Alexander ER, McMahan R. Epidemiology of Mycoplasma pneumoniae infection in families. JAMA. 1966;197(11):859-866
38. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53(5):2139-2141
39. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis. 2000;31(6):1507-1511
40. Cimolai N. Corticosteroids and complicated Mycoplasma pneumoniae infection. Pediatr Pulmonol. 2006;41(10):1008-1009 (Pubitemid 44534821)
41. Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006;41(3):263-268
42. Tagliabue C, Salvatore CM, Techasaensiri C, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008;198(8):1180-1188
43. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993;17(suppl 1):S37-S46 (Pubitemid 23227104)
44. Tanaka H, Narita M, Teramoto S, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest. 2002;121(5):1493-1497 (Pubitemid 34499661)
45. Chu HW, Campbell JA, Rino JG, Harbeck RJ, Martin RJ. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice. J Infect Dis. 2004;189(6):1119-1127 (Pubitemid 38373106)